SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for KCB003

HRP Western Blot Anti-Rabbit IgG Antibody

Overview

Description:	HRP Western Blot Anti-Rabbit IgG Antibody - KCB003
Item No.:	KCB003
Size:	100 µg
Applications:	WB
Host Species:	Goat

Product Details

Background:	Anti-Rabbit IgG peroxidase conjugated antibody generated in goat detects specifically rabbit IgG.
Synonyms:	Anti-Rabbit IgG Peroxidase Conjugated Antibody for Western Blot
Host Species:	Goat
Conjugate:	Peroxidase (HRP)
Clonality:	Polyclonal
Detection Kit Type:	Chemiluminescent Western Blot Kit

Target Details

Purity/Specificity:	HRP Western Blot Anti-Rabbit IgG Antibody was prepared from monospecific antiserum by immunoaffinity chromatography using Rabbit IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Peroxidase, anti-Goat Serum, Rabbit IgG and Rabbit Serum. No reaction was observed against Human Serum Proteins.

Application Details

Tested Applications:	WB
Application Note:	HRP Western Blot Anti-Rabbit IgG Antibody is specifically designed for immunoblotting used with Chemiluminescent Western Blot Kit (p/n KCA003) with Rabbit Primary Antibody.

Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Formulation

Concentration:	1.0 mg/ml by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Gentamicin Sulfate. Do NOT add Sodium Azide!

Shipping & Handling

Shipping Condition:	Wet Ice
Storage Condition:	See kit insert for complete instructions.
Expiration:	See kit insert for complete instructions.

Images



Western Blot
(A) LoVo cells were either exposed to PTHα (30 µM) or transfected with non-specific siRNA (ns-siRNA) or p14ARF specific siRNA. Cells were treated with 2.5 µM oxaliplatin 8 h after siRNA or 1 h after PTHα treatment. 120 h upon oxaliplatin exposure, the expression of p14ARF, p21CIP1, and p53, as well as the phosphorylation of p53 at Ser15 was measured by immunodetection. HRP conjugated goat anti-mouse (p/n KCB002) and HRP conjugated goat anti-rabbit (p/n KCB003) were used. Fig 7. PMID: 33922007.

References

- Tomicic MT et al. Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14 ARF-Mediated Sustained p53 Activation. *Cancers (Basel).* (2021)
- Schwarzenbach C et al. Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment. *Cancers (Basel).* (2021)

www.rockland.com
tech@rockland.com
+1 484.791.3823

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.